Search academic texts

Information × Registration Number 0221U104840, 0119U000575 , R & D reports Title To develop a method of combined treatment of melanoma patients with metastatic lesion of regional lymph nodes popup.stage_title Head Korovin Sergii I, д.мед.н. Registration Date 25-04-2021 Organization National Cancer Institute popup.description2 The toxicity of treatment was evaluated in experimental and control groups according to the criteria for assessing the toxicity of STSAE v4.0. In the analysis of toxicity of treatment of patients with metachronous metastases of melanoma in regional lymph nodes, which arose on the background of low-dose interferon therapy, it was found that in the observation group recorded the least number of side effects (anemia I-II in 4.8% of patients, weakness and weakness). -II century in 9.5%). Among patients receiving immunotherapy based on dendritic cells, 11.1% had anemia of I-II st., Weakness of I-II st. and nausea nonspecific immunotherapy with medium doses of interferon; in 22.2% - fever of I-II centuries. The greatest number of side effects was observed in patients receiving nonspecific immunotherapy with medium doses of interferon. In particular, 100% of patients had fever, 15% of them - III-IV centuries; 90% of patients complained of weakness of I-II degree, 20% had leukopenia and nausea of ​​I-II degree, 15% had anemia of I-II degree, 10% had arthralgia and nausea of ​​I-II degree. Toxicity analysis of treatment of patients with metachronous melanoma metastases in regional lymph nodes, which arose on the background of low-dose interferon therapy, showed that the use of nonspecific immunotherapy with medium doses of interferon and radiation therapy SVD 50-55G is associated with more -IV century. compared with monotherapy with average doses of interferon. In particular, the fever observed in 100% of patients in both groups, in the group of interferon and radiation had III-IV centuries. toxicity in 19.2% versus 7.4% in the interferon group. In addition, among patients receiving interferon and radiation therapy, 80.8% had general weakness I-II, 30.8% anemia I-II, 23.1% anemia and pain I-II Art., in 19.2% nausea I-II st., in 7.7% thrombocytopenia and arthralgia I-II st. Product Description popup.authors Dyedkov Serhiy A Kukushkina Mariia M Chornenʹkyy Denys O popup.nrat_date 2021-04-25 Close